What hormonal birth control prescription is appropriate for a reproductive‑age woman with primary dysmenorrhea?

Hormonal Birth Control for Primary Dysmenorrhea

For a reproductive-age woman with primary dysmenorrhea, prescribe combined oral contraceptives (COCs) as first-line hormonal therapy, with continuous or extended regimens providing superior pain relief compared to cyclic regimens, particularly in the first 3 months of treatment. 1, 2

Recommended Approach

First-Line Hormonal Options

Combined oral contraceptives are the preferred hormonal treatment for primary dysmenorrhea, demonstrating moderate to significant pain reduction compared to placebo (standardized mean difference -0.58) 1. The evidence shows:

• Pain improvement occurs in 37-60% of women using COCs versus 28% with placebo 1
• Continuous regimens outperform cyclic regimens in short-term pain relief (1-3 months), though this advantage diminishes by 6 months 2
• Both combined and progestin-only contraceptives are effective for primary and secondary dysmenorrhea 3

Specific Prescribing Recommendations

Start with low-dose COCs (20 μg ethinyl estradiol) combined with third or fourth-generation progestins:

• Desogestrel/ethinyl estradiol formulations have demonstrated efficacy in reducing menstrual pain severity and cramping 4
• No significant difference exists between 20 μg and 30 μg ethinyl estradiol formulations for pain relief 1
• Third and fourth-generation COCs show comparable efficacy to first and second-generation options 1

Consider continuous or extended regimens for enhanced pain control:

• Continuous use (no hormone-free interval) provides superior pain reduction in months 1-3 (mean difference -27.3 at 1 month, -17.8 at 3 months) 2
• After 6 months, both continuous and cyclic regimens achieve similar pain reduction 2
• Extended regimens reduce the frequency of withdrawal bleeding and associated pain episodes 5

Important Caveats and Side Effects

Expected Adverse Effects

Women should be counseled that COCs increase certain side effects compared to placebo:

• Irregular bleeding risk increases from 18% to 39-60% 1
• Headaches are 51% more likely (RR 1.51) 1
• Nausea is 64% more likely (RR 1.64) 1
• Overall adverse events increase by 31% (RR 1.31) 1

Continuous regimens reduce irregular bleeding compared to cyclic regimens (RR 1.38 for cyclic vs. continuous), making them preferable for women concerned about breakthrough bleeding 1.

Clinical Benefits Beyond Pain Relief

COCs provide additional advantages:

• Reduce need for additional pain medication by 37% (RR 0.63) 1
• Decrease work/school absence by 37% (RR 0.63) 1
• Provide reliable contraception without additional risk beyond standard COC use 6

When to Initiate Treatment

Treatment should not be delayed pending pelvic examination or definitive diagnosis 7. The diagnosis of primary dysmenorrhea requires only:

• Absence or low clinical suspicion of pelvic pathology (STI, PID, endometriosis, adenomyosis, fibroids, congenital anomalies) 8
• Pelvic examination is NOT required for diagnosis 8
• Ultrasound is not routinely indicated unless pelvic pathology is suspected 3

Alternative Hormonal Options

If COCs are contraindicated or not tolerated:

• Progestin-only contraceptives (pills, implants, LNG-IUD) are effective alternatives 3
• Levonorgestrel IUDs can be considered, though primarily studied for heavy bleeding rather than dysmenorrhea specifically 5

Comparison with NSAIDs

While NSAIDs remain first-line for women not desiring contraception 6, COCs are preferable for women seeking contraception because they:

• Provide comparable pain relief to NSAIDs 6
• Eliminate NSAID-related gastrointestinal and renal risks
• Offer a more suitable long-term treatment option 6
• Insufficient evidence exists to determine superiority between COCs and NSAIDs for pain alone 1

Management of Breakthrough Bleeding

If irregular bleeding occurs on continuous COCs, the 2024 CDC guidelines recommend 5:

• Provide reassurance that bleeding irregularities are common
• Avoid hormone-free intervals during the first 21 days of continuous use
• Limit hormone-free intervals to once per month (3-4 consecutive days) to maintain contraceptive effectiveness
• Consider method discontinuation only if patient desires